Navigation Links
FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Date:6/20/2008

anding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Millennium website is http://www.millennium.com.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com

Contacts:

Karen Gobler (Millennium) Seizo Masuda (Takeda)

(617) 444-1392 (011-81) 3-3278-2037

karen.gobler@mpi.com masuda_seizo@takeda.co.jp

Jennifer Snyder (Millennium)

(617) 444-1439

jennifer.snyder@mpi.com

(1) VELCADE as Initial Standard Therapy in multiple myeloma: Assessment

with melphalan and prednisone


'/>"/>
SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Japan Approves CyberKnife System for Extracranial Use
2. FDA approves NeuRx diaphragm pacing system for use in spinal cord- injured patients
3. FDA Approves Cymbalta(R) for the Management of Fibromyalgia
4. ClearWay Minnesota(SM) Board Approves $1.4 Million in New Grants to Reduce Tobaccos Harm
5. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
6. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
7. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
8. FDA Approves Health Claim for Brown Rice
9. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
10. FDA approves HeartMate II mechanical heart pump for heart-failure patients
11. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... 24Hr HomeCare is proud to announce that ... COO, and Ryan Iwamoto, Co-Founder & CMO, are Finalists ... 2015 Awards in Greater Los Angeles. The award is ... innovation, financial performance, and a personal commitment to their ... the ongoing success of our organization,” said Co-Founder & ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 According to ... ), market growth in hip external fixation market is ... aging U.S. population and advancements in infection prevention technologies. ... These fractures are currently accounting for the largest total ... associated with falls and accidents. As a result, the ...
(Date:5/25/2015)... May 25, 2015 A recent report for ... 1,000 persons have died as a direct result of an ... marks a 33% rise in overdose deaths attributed to prescription ... “This issue doesn’t care about geography. This issue doesn’t care ... doesn’t care about class.” As the state of Mass. reels ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 Stanley ... awards for design of the wastewater treatment ... Iowa.    The project received a National Recognition Award from the ... Award from ACEC – Iowa. Competitions held by ... , The $50.2 million expansion is Iowa City’s largest ...
(Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in the ... Court, Northern District of Texas. According to a ... asked the Court to modify the Case Management ... Health Information. Among other things, the Motion seeks ...
Breaking Medicine News(10 mins):Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 2Health News:DePuy Synthes and Stryker Lead Orthopedic External Fixation Trauma Device Market Due to Increased Hip Fractures in the U.S. 3Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3
... who are smokers and have a family history of brain aneurysm ... a brain aneurysm themselves. The research is published in the December ... of the American Academy of Neurology and will appear in the ... type of stroke, called subarachnoid hemorrhage, is one of the bleeding ...
... Priority in 2009SPRINGFIELD, Ill., Dec. 31 The following is ... Illinois:The economic situation is forcing more Illinois families to face ... of people are cutting back on necessities in order to ... it,s too expensive. High health care costs are leaving ...
... mcg/hr) Not Affected RARITAN, N.J., Dec. 31 PriCara(R), ... lot of 50 microgram/hour (mcg/hr) DURAGESIC(R) (fentanyl transdermal system) ... and one lot of 50 mcg/hr fentanyl patches sold ... voluntarily recalled as a precaution from wholesalers and pharmacies. ...
... XStor Medical Systems, a,privately held Silicon Valley ... advanced clinical applications and collaborative patient care.,The ... participating,hospitals, clinics, and healthcare systems to securely ... and patients. The,XStor Imaging Platform is a ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... today announced that its subsidiary, Watson Laboratories, Inc., ... and Drug Administration to market its over-the-counter Nicotine ... 2 mg and 4 mg strengths.Nicotine Polacrilex Gum, ...
... deprivation therapy that prostate cancer patients often take gives them ... within a couple of years. Now, researchers at Johns Hopkins ... cancer cells in patients who no longer respond to this ... Cancer Research , could lead to a way to ...
Cached Medicine News:Health News:Smokers with stroke in the family 6 times more likely to have stroke too 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2Health News:PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 3Health News:XStor Medical Systems Announces the Release of its Imaging Platform for Connectivity Between Healthcare Enterprises 2Health News:Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum 2Health News:Why prostate cancer patients fail hormone deprivation therapy 2
(Date:5/22/2015)... N.C. , May 22, 2015  Research ... hosting its sixth Medical Affairs Roundtable ... (EDT) via a virtual roundtable to discuss "Medical ... Best Practices, Medical Affairs Consortium provides ... insights about the key challenges they face. The ...
(Date:5/22/2015)... The Taskforce representing Canada,s living victims ... that the Minister and Health Canada have put into this ... needs of the thalidomide survivors, and more than 70% of ... with annual adjustments for inflation. Certain of the ... based on the severity of their disability, tax free, with ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... Corporation ( www.fluidnet.net ), an innovator of advanced intravenous ... Directors has unanimously appointed Benjamin E. Bulkley as President ... company,s Founder, Jeffrey Carlisle, who will serve as Fluidnet,s ... Board of Directors, Chuck Hadley, Chairman, said, "Fluidnet is ...
... Bulletin Board: IAGX ) announced today that based on ... of August that it expects its net sales for its second ... $2.8 to $3.2 million, an increase of 158% to 195% compared ... compared to the second quarter of the previous fiscal year. ...
Cached Medicine Technology:Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 2Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011 3
Anti-RSV IgA Assay (ELISA)....
... SAS RSV antigen test is ... for the presumptive qualitative detection ... from nasopharyngeal specimens in neonatal ... 15 minute test has a ...
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Medicine Products: